Fluoroquinolones: DNA Gyrase Inhibition, Clinical Indications and Serious Warnings

Educational review updated 10 November 2026. Antimicrobial selection and dosing must reflect patient factors, susceptibility data and current local guidance.

Overview

Fluoroquinolones are synthetic, concentration-dependent bactericidal antibiotics that inhibit bacterial type II topoisomerases. Their favorable oral absorption must be weighed against resistance and potentially severe adverse effects; they are not routine first-line agents for minor infections with safer effective alternatives [1,2].

Classification and spectrum

Representative drugs include ciprofloxacin (stronger activity against many Gram-negative organisms including susceptible Pseudomonas), levofloxacin (respiratory and some Gram-negative indications), moxifloxacin (respiratory/anaerobic activity but not preferred for urinary infection because of limited urine concentrations), and delafloxacin (selected approved indications). Spectrum varies by drug, pathogen and susceptibility; the old shorthand ‘generations’ is an imperfect prescribing guide [1].

Mechanism and resistance

Fluoroquinolones stabilize DNA cleavage complexes with DNA gyrase and topoisomerase IV, leading to double-strand DNA damage and bacterial death. Mutations in gyrA/gyrB and parC/parE, efflux, altered permeability and plasmid-mediated qnr protection contribute to resistance. Pharmacodynamics are generally assessed using free-drug AUC/MIC, not simply duration above MIC [1].

Appropriate clinical use

Depending on susceptibility and guidelines, fluoroquinolones may treat complicated urinary tract infection/pyelonephritis, certain bacterial prostatitis, selected severe respiratory infections, gastrointestinal pathogens and tuberculosis as part of specialized combination regimens. IDSA 2026 guidance prioritizes organism-specific choices for resistant Gram-negative infections and recommends preserving susceptibility and limiting toxicity [2]. Never treat uncomplicated viral illness with these agents [1,2].

PK and interactions

Oral bioavailability is high for many drugs. Renal-dose adjustment is commonly important for levofloxacin and ciprofloxacin; moxifloxacin is mainly nonrenally eliminated. Aluminum, magnesium, iron, zinc and calcium-containing products can chelate these drugs and markedly impair absorption; follow agent-specific spacing recommendations. Ciprofloxacin is a CYP1A2 inhibitor and can raise theophylline or tizanidine exposure; concomitant tizanidine is contraindicated [1].

Major warnings

Tendinitis and tendon rupture, peripheral neuropathy and central nervous system effects can be disabling and potentially persistent. Risks also include dysglycemia, QT prolongation (especially moxifloxacin), C. difficile infection, exacerbation of myasthenia gravis and possible aortic aneurysm/dissection in predisposed patients. Evaluate tendon symptoms, neuropathic symptoms, neuropsychiatric changes and cardiovascular risk promptly; reserve systemic therapy when safer alternatives are suitable [1].

Special populations

Pregnancy, childhood, epilepsy, renal dysfunction, transplant status and concurrent corticosteroids influence benefit–risk evaluation. Fluoroquinolones are not absolutely contraindicated in every pediatric setting; specialist-guided use may be appropriate for selected resistant infections [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Infectious Diseases Society of America. IDSA 2026 guidance on the treatment of antimicrobial resistant Gram-negative infections. 2026 Jul 30. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *